P867: TUMOR PROFILING OF IDECABTAGENE VICLEUCEL (IDE-CEL; BB2121) PATIENTS IN KARMMA SHOWED COMPARABLE RESPONSES IN EXISTING MOLECULAR HIGH-RISK SUBSETS AND PRELIMINARY GENE SIGNATURE OF DURABLE RESPONSE

• N. Martin,
• A. Xu,
• N. Stong,
• J. Rytlewski,
• O. Finney,
• T. Campbell,
• W. Pierceall,
• E. Flynt,
• E. Thompson,
• S. Kaiser

Affiliations

N. Martin

1 Bristol Myers Squibb, Princeton, NJ

A. Xu

1 Bristol Myers Squibb, Princeton, NJ

N. Stong

1 Bristol Myers Squibb, Princeton, NJ

J. Rytlewski

1 Bristol Myers Squibb, Princeton, NJ

O. Finney

2 2seventy bio, Boston, MA, United States of America

T. Campbell

1 Bristol Myers Squibb, Princeton, NJ

W. Pierceall

1 Bristol Myers Squibb, Princeton, NJ

E. Flynt

1 Bristol Myers Squibb, Princeton, NJ

E. Thompson

1 Bristol Myers Squibb, Princeton, NJ

S. Kaiser

1 Bristol Myers Squibb, Princeton, NJ